EUVIMEDEUVIMED entdecken
Open Access

Neoadjuvant Chemotherapy With the Angiogenesis Inhibitor Bevacizumab for Locally Advanced Cervical Cancer

Sunhwa Baek, Ka-Won Noh, Yue Zhao, Birgid Schoemig-Markiefka, Dominik Ratiu, Christian Domroese, Michael Mallmann, Peter Mallmann, Henryk Pilch

In Vivo · 2024-11 · 38 (6) · 3068-3077

DOI: 10.21873/invivo.13791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, online erschienen am 29.10.2024. Verfasst von Sunhwa Baek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University Hospital Cologne and Medical Faculty, Cologne, Germany; sunhwa.baek@uk-koeln.de. Hauptthemen laut MEDLINE: Bevacizumab, Uterine Cervical Neoplasms, Neoadjuvant Therapy, Neoplasm Staging. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: We hypothesized that adding bevacizumab to platinum-based neoadjuvant chemotherapy - whose efficacy for patients with recurrent or metastatic cervical cancer has already been proven - could optimize the therapy regimen, leading to improved response rates and survival outcomes. PATIENTS AND METHODS: Forty patients with histologically confirmed cervical cancer with FIGO stage IB3-IVA who received platinum-based neoadjuvant treatment between March 2008 and January 2019 in the Department of Obstetrics and Gynecology of University Hospital Cologne were analyzed. Twenty patients were treated with additional bevacizumab. The comparative cohort consisted of 18 patients treated with neoadjuvant chemotherapy alone. The response rates and clinical outcomes, including progression-free survival and overall survival, were evaluated. RESULTS: Neoadjuvant chemotherapy combined with bevacizumab significantly improved the response rate (p=0.046). The survival analysis showed that patients treated without bevacizumab had better progression-free survival up to FIGO stage IVA than patients treated with bevacizumab. However, overall survival was similar for both cohorts. For patients with advanced tumor stage, including FIGO IVB, progression-free survival and overall survival improved with the addition of bevacizumab. Pathological complete remission was a statistically significant prognostic factor for progression-free survival (p=0.039) but did not significantly affect overall survival (p=0.098). CONCLUSION: While bevacizumab did not demonstrate a significant improvement in overall survival rates, it was associated with a notable reduction in tumor size and showed a trend towards improved clinical response rates. These findings suggest that bevacizumab may have potential in optimizing the neoadjuvant treatment approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabUterine Cervical NeoplasmsNeoadjuvant TherapyNeoplasm StagingAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAdultAgedAngiogenesis InhibitorsTreatment OutcomePrognosis

Stichwörter der Autor:innen

Advanced cervical cancerangiogenesis inhibitorbevacizumabneoadjuvant chemotherapy

Substanzen

BevacizumabAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University Hospital Cologne and Medical Faculty, Cologne, Germany; sunhwa.baek@uk-koeln.de.
  • Institute for Pathology, University Hospital Cologne and Medical Faculty, Cologne, Germany.
  • Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne and Medical Faculty, Cologne, Germany.
  • Department of Obstetrics and Gynecology, University Hospital Cologne and Medical Faculty, Cologne, Germany.

Zitieren

APA

Baek, S., Noh, K. W., Zhao, Y., Schoemig-Markiefka, B., Ratiu, D., Domroese, C., Mallmann, M., Mallmann, P., & Pilch, H. (2024). Neoadjuvant Chemotherapy With the Angiogenesis Inhibitor Bevacizumab for Locally Advanced Cervical Cancer. In Vivo, 38(6), 3068-3077. https://doi.org/10.21873/invivo.13791

Vancouver

Baek S, Noh KW, Zhao Y, Schoemig-Markiefka B, Ratiu D, Domroese C, et al. Neoadjuvant Chemotherapy With the Angiogenesis Inhibitor Bevacizumab for Locally Advanced Cervical Cancer. In Vivo. 2024;38(6):3068-3077. doi:10.21873/invivo.13791

BibTeX
@article{Baek2024,
  author = {Baek, Sunhwa and Noh, Ka-Won and Zhao, Yue and Schoemig-Markiefka, Birgid and Ratiu, Dominik and Domroese, Christian and Mallmann, Michael and Mallmann, Peter and Pilch, Henryk},
  title = {Neoadjuvant Chemotherapy With the Angiogenesis Inhibitor Bevacizumab for Locally Advanced Cervical Cancer},
  journal = {In Vivo},
  year = {2024},
  volume = {38},
  number = {6},
  pages = {3068--3077},
  doi = {10.21873/invivo.13791}
}
Kostenlos starten →